Patient-specific Prescriptions for Non-food Producing Animals Gain Importance amid COVID-19 Pandemic
The revised draft guidance by the Food & Drug Administration (FDA) is supporting adherence to patient specific prescriptions for non-food producing animals. However, it is relatively challenging for companies in the animal drug compounding market to adapt toward this change amid uncertainties surrounding the COVID-19 pandemic.
In order to keep economies running during the ongoing COVID-19 outbreak, companies in the animal drug compounding market are boosting their output capacities to compound antidotes for food producing animals. Since livestock and pet owners are concerned for the health of their animals, manufacturers are being told to make innovations in FDA approved drugs as a starting point instead of beginning from active pharmaceutical ingredients (API).
Get the sample copy of report@ https://qyresearchmedical.com/sample/111824
Lack of Education for Equine Compounding Inhibit Market Growth
The animal drug compounding market is projected to climb a revenue growth from US$ 1 Bn in 2019 and cross US$ 1.7 Bn by 2030. However, it has been found that equine compounding is creating challenges for veterinarians and compounders due to lack of education. Hence, PCCA – a provider of complete resources for compounding pharmacies is helping companies in the animal drug compounding market to develop custom horse medications.
Veterinarians and compounders are becoming cognizant about guidelines issued for horses involved in equestrian sports. Strict rules of the Association of Racing Commissioners International (RCI) and the United States Equestrian Federation (USEF) help improve the quality of life in horses. Manufacturers are innovating in pain relievers, stimulants, and relaxing agents to tap into growth opportunities.
Ingredient Providers Helping Companies Innovate in Compounding for Exotic Animals
Companies in the animal drug compounding market are increasing efforts to maintain a full line of chemicals and supplies to support veterinary compounding. Letco Medical – a supplier of pharmaceutical ingredients, is gaining recognition for maintaining a formula database, which helps to find the right mixture for any animal. Manufacturers in the animal drug compounding market are working closely with ingredient suppliers who provide APIs, bases, flavors, and formulas that support veterinary compounding.
Manufacturers are focusing on quality assurance and compliance to stringent standards to bolster their credibility in the market landscape. Apart from dogs and cats, companies are increasing their compounding capabilities for horses, birds and other exotic animals that swim and fly.
Innovations in Veterinary-Anesthesia, Pain-Management Medications Boost Market Growth
Inorganic strategies, such as mergers and acquisitions are gaining prominence in the animal drug compounding market. Wedgewood Pharmacy – a PCAB®-accredited compounding pharmacy has announced the acquisition of Wildlife Pharmaceuticals, Inc. and its subsidiary ZooPharm to leverage incremental opportunities with innovations in veterinary-anesthesia and pain-management medications.
Manufacturers in the animal drug compounding market are extending their care for resident wildlife, non-domestic species, companion animals, and captive exotic breeds. They are increasing efforts to develop teams, co-ordinate resources, and expand customer relationships to boost company credentials. Companies are focusing on research and development to advance in specialized medications for managing aquariums, wildlife management organizations, conservation facilities, and private ranches.
Flavored Suspensions, Custom Medications Aid in Easy Administration of Pets
Custom-compounded medications have become a fast-growing phenomenon in the animal drug compounding market. Erie Pharmacy is gaining popularity for its comprehensive product portfolio in custom oral capsules, flavored suspensions, and compounded tablets. Since compounded drugs can be a life-saving option for difficult to medicate pets, owners are seeking consultation from veterinarians for compounding and customizing the strength of medication doses.
Factory made medication in many cases do not suit cats and dogs. Hence, companies in the animal drug compounding market are offering custom services in drug development to alter the medications as per specific doses and formulations that are easier to administer in pets. The combination of several ingredients has led to innovations in easy to swallow oral capsules. Flavored suspensions are serving as palatable options for pets that involve flavor enhancers such as fish, beef, peanut butter, and banana, among others.
Companies in the animal drug compounding market are establishing robust supply chains for customers at wildlife management organizations, private ranches, and conservation facilities, owing to COVID-19 travel restrictions. Companies are boosting their output capacities in compounded tablets and chews with flavored options for pets who are too sick to swallow. Patented combinations of butorphanol tartrate, azaperone tartrate, and medetomidine hydrochloride in medications aid in pain management. However, lack of education in equine compounding and stringent regulations by equestrian sports authorities are causing an impediment in market growth. Hence, companies should increase their production capabilities in compounding custom horse medication to overcome these challenges.
Animal Drug Compounding Market: Overview
The global animal drug compounding market was valued at US$ 1.1 Bn in 2019 and is projected to expand at a moderate CAGR from 2020 to 2030. Increase in demand for companion animals, rise in the number of licensed veterinarians or pharmacists, and limited number of FDA-approved drug products for several species and conditions are anticipated to boost the global animal drug compounding market during the forecast period.
Intermittent drug shortages and commercial unavailability of FDA-approved drug products drive the need of compounded preparations within veterinary practice. In species such as zoo animals, laboratory animals, exotic pets, wildlife, aquaria, and non-food aquaculture animals, the use of compounded preparations is paramount. Additionally, regulatory bodies are in the process of considering the critical need of access to compounded preparations within these species, which is a key factor driving the market.
View full report@ https://qyresearchmedical.com/report/animal-drug-compounding-market-product-anti-infectives-anti-inflammatory-cns-agents-gi-drugs-and-others-animal-type-companion-animal-and-livestock-animal-dosage-form-capsule-suspension-solution-powders-2020-2030/111824
Drug compounding is a process of mixing, combining, and altering the ingredients for developing tailor-made medications for animals. Compounded animal drugs are manufactured by veterinarians and pharmacists. Drug compounding is also considered when there are no appropriate drugs available for the treatment of a sick animal. Pharmacists consider two ways for compounding an animal drug: extra-label drugs and bulk ingredients. Compounded drugs are economical and most viable options for pet owners without insurance.
Veterinarians offer medical care through compounded drugs for various animal species such as zoo animals, exotic animals, and wild animals. Compounded drugs deliver vital medications to a patient; however, these drugs are not approved by the U.S. FDA.
Animal Drug Compounding Market: Segmentation
The global animal drug compounding market has been segmented based on product, animal type, dosage form, and route of administration
In terms of type, the global animal drug compounding market has been classified into anti-infectives, anti-inflammatory, CNS agents, GI drugs, and others. The CNS agents segment held the largest market share in 2019. The CNS agents segment has been segregated into potassium bromide, gabapentin, and other agents. CNS agents are highly prescribed medications in animals. Potassium bromide was among the most commonly prescribed drug, accounting for 48.7% market share, followed by diazepam, gabapentin, and fluoxetine. This is expected to fuel the growth of the segment during the forecast period.
Based on animal type, the global market has been bifurcated into companion animal and livestock. The companion animal segment accounted for the largest market share in 2019, which is ascribed to rise in pet ownership, easy availability of caring facilities, and rapid global urbanization. The global urban population has increased significantly from 0.75 billion in 1950 to 4.22 billion in 2018. This, in turn, is projected to drive the companion animal segment in the upcoming years.
In terms of dosage form, the global animal drug compounding market has been categorized into capsule, solution, powders, suspension, and others. The suspension segment held the largest market share in 2019. Oral suspension is a widely adopted drug administration method for animals. The taste of most drugs is less noticeable in suspension compared to solution, as the drug is less soluble in suspension. For instance, itraconazole is a common drug administered in oral suspension form.
Based on route of administration, the global animal drug compounding market has been divided into oral, injectable, topical, rectal, and ocular. The oral segment accounted for the largest market share in 2019, attributed to rise in number of pet ownerships and incidence of diseases in animals.
Animal Drug Compounding Market: Regional Segmentation
In terms of region, the global animal drug compounding market has been segmented North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
North America dominated the global animal drug compounding market in 2019. This is ascribed to well-established market, large number of pharmacists and focus on addressing drug shortages. Moreover, ideal regulation by the FDA is likely to augment the animal drug compounding market in North America. Favorable regulatory policies and rise in demand for customized compounded medication to meet the needs of small animals drive the market in the region.
The market in Asia Pacific is projected to grow at a rapid pace during the forecast period. Well-established healthcare infrastructure and rise in acceptance of compounded veterinary preparations are the key factors anticipated to propel the market in the region. Rise in pet ownership is expected to drive the animal drug compounding market in the region.
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111824/2900
Animal Drug Compounding Market: Major Players
Key players operating in the global animal drug compounding market include
- Wedgewood Pharmacy
- Triangle Compounding Pharmacy
- Davis Islands Pharmacy
- Custom Med Compounding Pharmacy
- Central Compounding Center South
- Wellness Pharmacy of Cary
- Caringbah Compounding Pharmacy
- Millers Pharmacy
- Smith’s Pharmacy
These players focus on adopting various strategies for the expansion of product offerings, development of personalized and emergency compounded drugs, and strategies to strengthen geographic presence. Moreover, companies offer loyalty programs, as new players enter the market with end-to-end solutions.
Key Questions Answered in Animal Drug Compounding Market Report
- What are the sales/revenue generated by animal drug compounding across all regions during the forecast period?
- What are the key trends in the global animal drug compounding market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which region is set to expand at the fastest CAGR during the forecast period?
- Which segment will have the highest revenue globally in 2030 and which segment will grow at the highest CAGR during the forecast period?
- What was the market share of different companies operating in the global market in 2019?
- What were the strengths and weaknesses of major players in 2019?
- What was the competitive analysis of major players in 2019?
- What was the market share analysis of different companies operating in the global market in 2019?
Animal Drug Compounding Market – Segmentation
- Other Antibiotics
- Other Anti inflammatory
- CNS Agents
- Potassium bromide
- Other CNS agents
- GI Drugs
- Other GI Drugs
- Other drugs
- Companion Animal
- Livestock Animal
Route of Administration
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
TABLE OF CONTENT
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Global Animal Drug Compounding Market Analysis and Forecast, by Product
3.1. Introduction & Definition
3.2. Key Findings / Developments
3.3. Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Product, 2018–2030
220.127.116.11. Other Antibiotics
18.104.22.168. Other Anti inflammatory
3.3.3. CNS Agents
22.214.171.124. Potassium bromide
126.96.36.199. Other CNS agents
3.3.4. GI Drugs
188.8.131.52. Other GI Drugs
184.108.40.206. Other drugs
3.4. Market Attractiveness Analysis, by Product
4. Global Animal Drug Compounding Market Analysis and Forecast, by Animal Type
4.1. Introduction & Definition
4.2. Key Findings / Developments
4.3. Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Animal Type, 2018–2030
4.3.1. Companion Animal
4.4. Global Animal Drug Compounding Market Attractiveness Analysis, by Animal Type
5. Global Animal Drug Compounding Market Analysis and Forecast, by Dosage Form
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030
5.4. Global Animal Drug Compounding Market Attractiveness Analysis, by Dosage Form
6. Global Animal Drug Compounding Market Analysis and Forecast, by Route of Administration
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
6.4. Global Animal Drug Compounding Market Attractiveness Analysis, by Route of Administration
7. Global Animal Drug Compounding Market Analysis and Forecast, by Region
7.1. Key Findings
7.2. Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Region
7.2.1. North America
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. Global Animal Drug Compounding Market Attractiveness Analysis, by Region
8. North America Animal Drug Compounding Market Analysis and Forecast
8.1.1. Key Findings
8.2. North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Product, 2018–2030
220.127.116.11. Other Antibiotics
18.104.22.168. Other Anti inflammatory
8.2.3. CNS Agents
22.214.171.124. Potassium Bromide
126.96.36.199. Other CNS agents
8.2.4. GI Drugs
188.8.131.52. Other GI Drugs
184.108.40.206. Other drugs
8.3. North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Animal Type, 2018–2030
8.3.1. Companion Animal
8.3.2. Livestock Animal
8.4. North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030
8.5. North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
8.6. North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
9. Europe Animal Drug Compounding Market Analysis and Forecast
9.1.1. Key Findings
9.2. Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Product, 2018–2030
220.127.116.11. Other Antibiotics
18.104.22.168. Other Anti inflammatory
9.2.3. CNS Agents
22.214.171.124. Potassium Bromide
126.96.36.199. Other CNS agents
9.2.4. GI Drugs
188.8.131.52. Other GI Drugs
184.108.40.206. Other drugs
9.3. Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Animal Type, 2018–2030
9.3.1. Companion Animal
9.3.2. Livestock Animal
9.4. Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030
9.5. Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
9.6. Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
9.6.6. Rest of Europe
10. Asia Pacific Animal Drug Compounding Market Analysis and Forecast
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111824/2900
You can place an order or ask any questions, please feel free to contact email@example.com | +1 9197 992 333
QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.
For Latest Update Follow Us: